Amy Abernethy

Amy P. Abernethy, MD, PhD is the President of Clinical Studies Platforms at Alphabet’s Verily, where she has responsibility for the company’s Baseline program and other initiatives to support clinical trials and real-world evidence (RWE) studies.

Before joining Verily, Dr. Abernethy was Principal Deputy Commissioner and Acting Chief Information Officer of the US Food & Drug Administration. Prior roles include serving as CMO/CSO of Flatiron Health and multiple roles at Duke University, where she was Professor of Medicine.

Dr. Abernethy went to the University of Pennsylvania and then Duke University Medical School, and received her PhD from Flinders University in Australia.